| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.837 | 0.001 | 0.837 | Benzodiazepine agonist | 0.739 0.002 DBMET00280 0.479 0.003 DBMET00112 0.783 0.002 DBMET00632 | ||
| 0.813 | 0.004 | 0.869 | Platelet aggregation inhibitor | 0.784 0.004 DBMET00280 0.821 0.004 DBMET00112 0.869 0.004 DBMET00632 | DBMET00632 | |
| 0.794 | 0.002 | 0.834 | GABA receptor agonist | 0.834 0.002 DBMET00280 0.641 0.003 DBMET00112 0.789 0.002 DBMET00632 | DBMET00280 | |
| 0.776 | 0.004 | 0.845 | Platelet activating factor antagonist | 0.719 0.004 DBMET00280 0.744 0.004 DBMET00112 0.845 0.003 DBMET00632 | DBMET00632 | |
| 0.753 | 0.005 | 0.923 | Anticonvulsant | 0.796 0.004 DBMET00280 0.852 0.004 DBMET00112 0.923 0.003 DBMET00632 | DBMET00632 | |
| 0.617 | 0.006 | 0.732 | GABA C receptor rho-3 antagonist | 0.644 0.004 DBMET00280 0.621 0.005 DBMET00112 0.732 0.003 DBMET00632 | DBMET00632 | |
| 0.615 | 0.005 | 0.683 | Psychostimulant | 0.442 0.017 DBMET00280 0.683 0.004 DBMET00112 0.643 0.005 DBMET00632 | DBMET00112 | |
| 0.466 | 0.003 | 0.755 | GABA A receptor antagonist | 0.407 0.004 DBMET00280 0.567 0.003 DBMET00112 0.755 0.002 DBMET00632 | DBMET00632 | |
| 0.445 | 0.004 | 0.749 | GABA receptor antagonist | 0.431 0.004 DBMET00280 0.58 0.003 DBMET00112 0.749 0.003 DBMET00632 | DBMET00632 | |
| 0.269 | 0.005 | 0.431 | GABA A receptor agonist | 0.204 0.009 DBMET00280 0.267 0.005 DBMET00112 0.431 0.004 DBMET00632 | DBMET00632 | |
| 0.282 | 0.042 | 0.282 | Sigma receptor agonist | |||
| 0.331 | 0.108 | 0.331 | MAP kinase kinase 6 inhibitor | 0.237 0.208 DBMET00280 0.28 0.155 DBMET00632 | ||
| 0.234 | 0.015 | 0.327 | GABA C receptor rho-2 antagonist | 0.233 0.016 DBMET00280 0.243 0.013 DBMET00112 0.327 0.004 DBMET00632 | DBMET00632 | |
| 0.21 | 0.005 | 0.345 | Vasopressin 1 antagonist | 0.235 0.004 DBMET00280 0.345 0.004 DBMET00112 0.068 0.012 DBMET00632 | DBMET00112 | |
| 0.322 | 0.125 | 0.322 | Analgesic | |||
| 0.199 | 0.005 | 0.287 | Antidiuretic hormone antagonist | 0.223 0.005 DBMET00280 0.287 0.004 DBMET00112 0.084 0.015 DBMET00632 | DBMET00112 | |
| 0.252 | 0.062 | 0.261 | Cyclic AMP phosphodiesterase inhibitor | 0.261 0.059 DBMET00112 0.197 0.096 DBMET00632 | DBMET00112 | |
| 0.243 | 0.074 | 0.243 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.238 0.082 DBMET00280 0.199 0.168 DBMET00112 0.233 0.09 DBMET00632 | ||
| 0.17 | 0.005 | 0.17 | Bromodomain-containing protein 2 inhibitor | 0.137 0.014 DBMET00280 0.152 0.008 DBMET00112 0.114 0.027 DBMET00632 | ||
| 0.157 | 0.003 | 0.157 | Benzodiazepine antagonist | 0.074 0.006 DBMET00280 0.065 0.009 DBMET00112 0.148 0.003 DBMET00632 | ||
| 0.14 | 0.007 | 0.14 | Bromodomain-containing protein 4 inhibitor | 0.116 0.01 DBMET00280 0.111 0.011 DBMET00112 0.061 0.031 DBMET00632 | ||
| 0.233 | 0.101 | 0.273 | Gastrin inhibitor | 0.245 0.085 DBMET00280 0.22 0.119 DBMET00112 0.273 0.055 DBMET00632 | DBMET00632 | |
| 0.13 | 0.004 | 0.13 | Bromodomain-containing protein 3 inhibitor | 0.119 0.004 DBMET00280 0.124 0.004 DBMET00112 0.069 0.013 DBMET00632 | ||
| 0.123 | 0.005 | 0.266 | Vasopressin 1A antagonist | 0.165 0.004 DBMET00280 0.266 0.004 DBMET00112 0.058 0.011 DBMET00632 | DBMET00112 | |
| 0.11 | 0.007 | 0.116 | Cholecystokinin A antagonist | 0.116 0.007 DBMET00280 0.053 0.018 DBMET00112 0.098 0.009 DBMET00632 | DBMET00280 | |
| 0.109 | 0.008 | 0.117 | Phosphodiesterase 1A inhibitor | 0.058 0.047 DBMET00280 0.056 0.051 DBMET00112 0.117 0.007 DBMET00632 | DBMET00632 | |
| 0.172 | 0.081 | 0.172 | MAP kinase kinase 5 inhibitor | |||
| 0.095 | 0.01 | 0.211 | Oxytocin antagonist | 0.094 0.01 DBMET00280 0.211 0.004 DBMET00112 | DBMET00112 | |
| 0.092 | 0.009 | 0.092 | Cholecystokinin antagonist | 0.09 0.009 DBMET00280 0.054 0.023 DBMET00112 0.079 0.012 DBMET00632 | ||
| 0.108 | 0.037 | 0.108 | Histamine H1 receptor antagonist | |||
| 0.097 | 0.027 | 0.125 | Protein kinase B beta inhibitor | 0.125 0.013 DBMET00280 0.073 0.052 DBMET00112 0.108 0.021 DBMET00632 | DBMET00280 | |
| 0.112 | 0.044 | 0.112 | Phosphodiesterase 7B inhibitor | 0.096 0.061 DBMET00280 0.09 0.071 DBMET00112 | ||
| 0.118 | 0.054 | 0.185 | GABA C receptor antagonist | 0.185 0.016 DBMET00280 0.126 0.047 DBMET00112 0.17 0.021 DBMET00632 | DBMET00280 | |
| 0.111 | 0.049 | 0.183 | GABA C receptor rho-1 antagonist | 0.149 0.022 DBMET00280 0.131 0.032 DBMET00112 0.183 0.011 DBMET00632 | DBMET00632 | |
| 0.109 | 0.049 | 0.109 | Pim-1 kinase inhibitor | 0.096 0.062 DBMET00632 | ||
| 0.114 | 0.056 | 0.114 | Interleukin 2 antagonist | 0.106 0.073 DBMET00280 0.103 0.083 DBMET00112 | ||
| 0.203 | 0.154 | 0.245 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.245 0.111 DBMET00632 | DBMET00632 | |
| 0.07 | 0.023 | 0.089 | Phosphodiesterase II inhibitor | 0.058 0.035 DBMET00280 0.089 0.014 DBMET00112 0.076 0.019 DBMET00632 | DBMET00112 | |
| 0.051 | 0.006 | 0.051 | Benzodiazepine receptor peripheral-type antagonist | 0.037 0.019 DBMET00280 0.033 0.026 DBMET00112 0.042 0.011 DBMET00632 | ||
| 0.114 | 0.071 | 0.126 | Cholesterol synthesis inhibitor | 0.126 0.06 DBMET00112 | DBMET00112 | |
| 0.062 | 0.022 | 0.144 | Purinergic P2X antagonist | 0.057 0.026 DBMET00280 0.144 0.005 DBMET00632 | DBMET00632 | |
| 0.062 | 0.023 | 0.08 | Phosphodiesterase 2A inhibitor | 0.05 0.034 DBMET00280 0.08 0.014 DBMET00112 0.069 0.019 DBMET00632 | DBMET00112 | |
| 0.067 | 0.034 | 0.121 | Phosphodiesterase 1C inhibitor | 0.058 0.053 DBMET00280 0.077 0.022 DBMET00112 0.121 0.006 DBMET00632 | DBMET00632 | |
| 0.091 | 0.058 | 0.131 | Phosphodiesterase I inhibitor | 0.131 0.022 DBMET00632 | DBMET00632 | |
| 0.045 | 0.018 | 0.105 | Purinergic P2X7 antagonist | 0.04 0.021 DBMET00280 0.105 0.005 DBMET00632 | DBMET00632 | |
| 0.044 | 0.017 | 0.047 | CF transmembrane conductance regulator antagonist | 0.047 0.012 DBMET00112 | DBMET00112 | |
| 0.066 | 0.042 | 0.182 | Purinergic P2 antagonist | 0.06 0.048 DBMET00280 0.182 0.008 DBMET00632 | DBMET00632 | |
| 0.05 | 0.026 | 0.066 | Benzodiazepine inverse agonist | 0.05 0.026 DBMET00280 0.056 0.018 DBMET00112 0.066 0.011 DBMET00632 | DBMET00632 | |
| 0.128 | 0.106 | 0.164 | Pregnane X receptor agonist | 0.141 0.072 DBMET00112 0.164 0.032 DBMET00632 | DBMET00632 | |
| 0.056 | 0.038 | 0.065 | MAP kinase kinase 9 inhibitor | 0.065 0.025 DBMET00632 | DBMET00632 | |
| 0.118 | 0.1 | 0.16 | Nav1.6 sodium channel blocker | 0.16 0.043 DBMET00280 | DBMET00280 | |
| 0.073 | 0.059 | 0.111 | GABA B receptor agonist | 0.111 0.01 DBMET00280 0.082 0.038 DBMET00112 0.077 0.049 DBMET00632 | DBMET00280 | |
| 0.043 | 0.029 | 0.045 | Alpha 1L adrenoreceptor agonist | 0.041 0.034 DBMET00280 0.041 0.034 DBMET00112 0.045 0.024 DBMET00632 | DBMET00632 | |
| 0.057 | 0.048 | 0.057 | Adrenaline uptake inhibitor | |||
| 0.161 | 0.153 | 0.161 | Spasmolytic | |||
| 0.04 | 0.034 | 0.04 | Nerve growth factor antagonist | |||
| 0.163 | 0.163 | 0.179 | 5 Hydroxytryptamine 3E antagonist | 0.179 0.109 DBMET00632 | DBMET00632 | |
| 0.041 | 0.045 | 0.05 | Parathyroid hormone antagonist | 0.046 0.03 DBMET00280 0.047 0.027 DBMET00112 0.05 0.022 DBMET00632 | DBMET00632 | |
| 0.026 | 0.032 | 0.035 | Vasopressin 2 antagonist | 0.035 0.021 DBMET00112 | DBMET00112 | |
| 0.051 | 0.058 | 0.126 | Phosphodiesterase 1B inhibitor | 0.058 0.044 DBMET00112 0.126 0.009 DBMET00632 | DBMET00632 | |
| 0.039 | 0.046 | 0.108 | AMPA receptor antagonist | 0.044 0.037 DBMET00280 0.066 0.022 DBMET00112 0.108 0.01 DBMET00632 | DBMET00632 | |
| 0.094 | 0.105 | 0.168 | Glutamate receptor antagonist | 0.119 0.074 DBMET00280 0.168 0.04 DBMET00112 0.158 0.046 DBMET00632 | DBMET00112 | |
| 0.099 | 0.113 | 0.173 | Sodium channel (voltage-gated) blocker | 0.15 0.054 DBMET00280 0.126 0.078 DBMET00112 0.173 0.041 DBMET00632 | DBMET00632 | |
| 0.086 | 0.105 | 0.115 | MAP kinase 13 inhibitor | 0.101 0.08 DBMET00280 0.115 0.061 DBMET00632 | DBMET00632 | |
| 0.066 | 0.085 | 0.077 | Glycine receptor antagonist | 0.077 0.062 DBMET00112 0.075 0.065 DBMET00632 | DBMET00112 | |
| 0.056 | 0.076 | 0.107 | MAP kinase kinase 8 inhibitor | 0.107 0.019 DBMET00632 | DBMET00632 | |
| 0.116 | 0.142 | 0.179 | LIM domain kinase 1 inhibitor | 0.179 0.074 DBMET00632 | DBMET00632 | |
| 0.038 | 0.064 | 0.091 | Histamine H4 receptor antagonist | 0.091 0.006 DBMET00632 | DBMET00632 | |
| 0.033 | 0.062 | 0.081 | GABA B receptor antagonist | 0.058 0.013 DBMET00280 0.047 0.023 DBMET00112 0.081 0.006 DBMET00632 | DBMET00632 | |
| 0.044 | 0.076 | 0.055 | 5 Hydroxytryptamine 7 agonist | 0.055 0.041 DBMET00632 | DBMET00632 | |
| 0.028 | 0.062 | 0.171 | Nicotinic acid receptor 1 agonist | 0.037 0.033 DBMET00112 0.171 0.004 DBMET00632 | DBMET00632 | |
| 0.05 | 0.085 | 0.074 | Protein kinase B alpha inhibitor | 0.074 0.044 DBMET00280 0.074 0.044 DBMET00632 | DBMET00632 | |
| 0.063 | 0.1 | 0.089 | Falcipain 2 inhibitor | 0.089 0.06 DBMET00632 | DBMET00632 | |
| 0.064 | 0.104 | 0.09 | Falcipain inhibitor | 0.09 0.063 DBMET00632 | DBMET00632 | |
| 0.082 | 0.126 | 0.096 | Nav1.5 sodium channel blocker | 0.096 0.093 DBMET00632 | DBMET00632 | |
| 0.028 | 0.071 | 0.049 | 5 Hydroxytryptamine 2B agonist | 0.049 0.014 DBMET00280 | DBMET00280 | |
| 0.027 | 0.072 | 0.065 | Glutamate (mGluR5) antagonist | 0.065 0.019 DBMET00632 | DBMET00632 | |
| 0.032 | 0.077 | 0.042 | Farnesyltransferase inhibitor | 0.042 0.038 DBMET00632 | DBMET00632 | |
| 0.063 | 0.114 | 0.084 | Antihistaminic | 0.084 0.072 DBMET00632 | DBMET00632 | |
| 0.095 | 0.149 | 0.183 | Diuretic | 0.163 0.067 DBMET00280 0.124 0.1 DBMET00112 0.183 0.052 DBMET00632 | DBMET00632 | |
| 0.031 | 0.088 | 0.052 | Purinergic P2X4 antagonist | 0.052 0.022 DBMET00632 | DBMET00632 | |
| 0.053 | 0.111 | 0.075 | Histamine antagonist | 0.075 0.07 DBMET00632 | DBMET00632 | |
| 0.114 | 0.174 | 0.148 | MAP kinase kinase 4 inhibitor | 0.129 0.116 DBMET00280 0.135 0.1 DBMET00112 0.148 0.065 DBMET00632 | DBMET00632 | |
| 0.044 | 0.109 | 0.094 | Glutamate (mGluR group I) antagonist | 0.094 0.029 DBMET00632 | DBMET00632 | |
| 0.066 | 0.131 | 0.123 | DNA intercalator | 0.123 0.056 DBMET00632 | DBMET00632 | |
| 0.006 | 0.072 | 0.039 | AMPA 1 receptor antagonist | 0.039 0.015 DBMET00632 | DBMET00632 | |
| 0.043 | 0.109 | 0.072 | Corticotropin releasing factor 2 receptor antagonist | 0.072 0.026 DBMET00632 | DBMET00632 | |
| 0.044 | 0.124 | 0.096 | Glutamate (mGluR) antagonist | 0.068 0.063 DBMET00112 0.096 0.037 DBMET00632 | DBMET00632 | |
| 0.094 | 0.175 | 0.154 | Cyclin-dependent kinase 8 inhibitor | 0.154 0.075 DBMET00632 | DBMET00632 | |
| 0.027 | 0.107 | 0.061 | Toll-Like receptor 8 antagonist | 0.061 0.03 DBMET00112 0.059 0.032 DBMET00632 | DBMET00112 | |
| 0.055 | 0.137 | 0.082 | Potassium channel activator | 0.082 0.072 DBMET00632 | DBMET00632 | |
| 0.077 | 0.164 | 0.131 | Thrombolytic | 0.131 0.098 DBMET00112 | DBMET00112 | |
| 0.019 | 0.11 | 0.047 | Factor XIa inhibitor | 0.047 0.021 DBMET00280 | DBMET00280 | |
| 0.057 | 0.151 | 0.098 | Phosphodiesterase XI inhibitor | 0.098 0.034 DBMET00280 | DBMET00280 | |
| 0.057 | 0.151 | 0.098 | Phosphodiesterase 11A inhibitor | 0.098 0.034 DBMET00280 | DBMET00280 | |
| 0.227 | 0.329 | 0.322 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.322 0.184 DBMET00632 | DBMET00632 | |
| 0.057 | 0.166 | 0.089 | mTOR complex 2 inhibitor | 0.089 0.049 DBMET00632 | DBMET00632 | |
| 0.057 | 0.165 | 0.098 | 5 Hydroxytryptamine 3A agonist | 0.094 0.084 DBMET00280 0.098 0.079 DBMET00632 | DBMET00632 | |
| 0.049 | 0.17 | 0.077 | MDM2 inhibitor | 0.065 0.053 DBMET00112 0.077 0.023 DBMET00632 | DBMET00632 | |
| 0.096 | 0.219 | 0.161 | Interleukin agonist | 0.161 0.157 DBMET00112 | DBMET00112 | |
| 0.044 | 0.168 | 0.071 | Phosphodiesterase VIII inhibitor | 0.071 0.052 DBMET00112 | DBMET00112 | |
| 0.033 | 0.157 | 0.093 | Nav1.7 sodium channel blocker | 0.093 0.026 DBMET00632 | DBMET00632 | |
| 0.024 | 0.154 | 0.062 | 5 Hydroxytryptamine 2A agonist | 0.062 0.044 DBMET00280 | DBMET00280 | |
| 0.061 | 0.199 | 0.116 | Sodium channel blocker | 0.116 0.088 DBMET00280 0.114 0.092 DBMET00632 | DBMET00280 | |
| 0.017 | 0.155 | 0.057 | Adenosine A1 receptor antagonist | 0.057 0.042 DBMET00632 | DBMET00632 | |
| 0.007 | 0.146 | 0.028 | Kynurenine 3 monooxygenase inhibitor | 0.028 0.017 DBMET00632 | DBMET00632 | |
| 0.052 | 0.191 | 0.077 | MAP kinase kinase 7 inhibitor | 0.077 0.055 DBMET00632 | DBMET00632 | |
| 0.016 | 0.159 | 0.063 | Glutamate (mGluR1) antagonist | 0.063 0.036 DBMET00632 | DBMET00632 | |
| 0.028 | 0.185 | 0.094 | Leucine-rich repeat kinase 2 inhibitor | 0.094 0.046 DBMET00632 | DBMET00632 | |
| 0.042 | 0.208 | 0.094 | Creatine kinase inhibitor | 0.094 0.066 DBMET00632 | DBMET00632 | |
| 0.024 | 0.192 | 0.088 | Toll-Like receptor 7 antagonist | 0.088 0.03 DBMET00632 | DBMET00632 | |
| 0.181 | 0.363 | 0.536 | Antiinflammatory | 0.536 0.073 DBMET00112 0.42 0.128 DBMET00632 | DBMET00112 | |
| 0.008 | 0.19 | 0.048 | 5 Hydroxytryptamine 2C agonist | 0.048 0.029 DBMET00280 | DBMET00280 | |
| 0.047 | 0.231 | 0.106 | MAP kinase 12 inhibitor | 0.106 0.089 DBMET00632 | DBMET00632 | |
| 0.015 | 0.202 | 0.046 | AMPA 4 receptor antagonist | 0.046 0.018 DBMET00632 | DBMET00632 | |
| 0.045 | 0.233 | 0.111 | Polo-like kinase-1 inhibitor | 0.111 0.036 DBMET00632 | DBMET00632 | |
| 0.045 | 0.24 | 0.096 | DNA directed RNA polymerase inhibitor | 0.096 0.061 DBMET00280 | DBMET00280 | |
| 0.047 | 0.244 | 0.126 | Lanosterol 14 alpha demethylase inhibitor | 0.126 0.025 DBMET00632 | DBMET00632 | |
| 0.042 | 0.246 | 0.105 | Proto-oncogene tyrosine-protein kinase Yes inhibitor | 0.105 0.096 DBMET00632 | DBMET00632 | |
| 0.117 | 0.321 | 0.179 | ErbB-1 antagonist | 0.179 0.117 DBMET00632 | DBMET00632 | |
| 0.034 | 0.248 | 0.069 | Exportin-1 inhibitor | 0.069 0.046 DBMET00632 | DBMET00632 | |
| 0.025 | 0.243 | 0.128 | Protein kinase (CK1) delta inhibitor | 0.128 0.067 DBMET00632 | DBMET00632 | |
| 0.053 | 0.277 | 0.112 | Toll-Like receptor antagonist | 0.112 0.099 DBMET00112 | DBMET00112 | |
| 0.051 | 0.288 | 0.098 | Hedgehog signaling inhibitor | 0.098 0.068 DBMET00632 | DBMET00632 | |
| 0.032 | 0.274 | 0.153 | Topoisomerase II inhibitor | 0.153 0.048 DBMET00632 | DBMET00632 | |
| 0.1 | 0.364 | 0.191 | RNA-directed DNA polymerase inhibitor | 0.191 0.113 DBMET00112 0.179 0.135 DBMET00632 | DBMET00112 | |
| 0.006 | 0.273 | 0.024 | Factor IX inhibitor | 0.024 0.009 DBMET00632 | DBMET00632 | |
| 0.021 | 0.291 | 0.201 | Topoisomerase II alpha inhibitor | 0.201 0.015 DBMET00632 | DBMET00632 | |
| 0.019 | 0.293 | 0.112 | 5 Hydroxytryptamine 1B agonist | 0.112 0.005 DBMET00632 | DBMET00632 | |
| 0.022 | 0.299 | 0.116 | MAP kinase kinase kinase inhibitor | 0.116 0.053 DBMET00632 | DBMET00632 | |
| 0.06 | 0.347 | 0.141 | Antipruritic | 0.141 0.105 DBMET00632 | DBMET00632 | |
| 0.012 | 0.334 | 0.042 | MAP3K5 inhibitor | 0.042 0.022 DBMET00632 | DBMET00632 | |
| 0.033 | 0.364 | 0.155 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | 0.155 0.126 DBMET00632 | DBMET00632 | |
| 0.038 | 0.385 | 0.164 | Nav1.1 sodium channel blocker | 0.164 0.028 DBMET00280 | DBMET00280 | |
| 0.031 | 0.383 | 0.146 | Dyrk kinase inhibitor | 0.146 0.14 DBMET00632 | DBMET00632 | |
| 0.017 | 0.386 | 0.082 | Alcohol dehydrogenase inhibitor | 0.082 0.077 DBMET00632 | DBMET00632 | |
| 0.042 | 0.459 | 0.124 | Hexokinase inhibitor | 0.124 0.113 DBMET00632 | DBMET00632 | |
| 0.005 | 0.446 | 0.085 | 5 Hydroxytryptamine agonist | 0.085 0.039 DBMET00632 | DBMET00632 | |
| 0.062 | 0.516 | 0.223 | Immunomodulator | 0.21 0.152 DBMET00112 0.223 0.139 DBMET00632 | DBMET00632 | |
| 0.017 | 0.581 | 0.086 | Polo-like kinase-2 inhibitor | 0.086 0.038 DBMET00632 | DBMET00632 | |
| 0.013 | 0.592 | 0.316 | M18 aspartyl aminopeptidase inhibitor | 0.316 0.011 DBMET00632 | DBMET00632 | |
| 0.004 | 0.585 | 0.095 | 5 Hydroxytryptamine 1 agonist | 0.095 0.022 DBMET00632 | DBMET00632 | |
| 0.028 | 0.632 | 0.083 | T cell inhibitor | 0.083 0.057 DBMET00632 | DBMET00632 | |
| 0.018 | 0.691 | 0.157 | Nav1.4 sodium channel blocker | 0.157 0.031 DBMET00280 | DBMET00280 | |
| 0.012 | 0.727 | 0.048 | Factor IXa inhibitor | 0.048 0.04 DBMET00632 | DBMET00632 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |